Published: 2020-02-26

Role of ormeloxifene in regression of benign breast diseases

Girish T. U., Mohammad Faraz


Background: Benign breast diseases are common pathological entities with which women in her early reproductive age present to OPD with fear of malignancy and significant morbidity. Except for surgery and use of non-selective estrogen receptor blockers, there are no other treatment options, and these have lot side effects. Ormeloxifene a newer drug has shown promising results with minimal side effects and used as the first line of treatment reducing the morbidity of surgery and subjecting the patient to less hormonal side effects.

Methods: Diagnosis of benign breast diseases was made by baseline investigation which included measurement of size of fibroadenoma using Vernier caliper and USG, fibroadenosis,ie nodularity measured using  Lucknow-Cardiff scale and VAS score was used for pain assessment of mastalgia after which patients will be given the drug and  placebo and the response for the drug and its side effects are noted.

Results: 61.9% (44) were diagnosed with fibroadenoma, 16.9% (12) with fibroadenosis and 21.1% (15) with mastalgia. Lucknow Cardiff score for fibroadenosis exhibited 50% had smooth breasts with no nodularity at the end of six months, in fibroadenoma group 52% showed decrease in size and 31% showed complete disappearance of the lump and in the mastalgia group 40% had no pain (VAS score of 0). 16(22.5%) of had menstrual abnormality as the major side effect.

Conclusions: Ormeloxifene can be used as the first line of treatment in patients with fibroadenosis and mastalgia and used as an alternative to surgery for fibroadenoma. 


Benign breast diseases, Fibroadenoma, Fibroadenosis, Mastalgia, Ormeloxifene

Full Text:



Miltenburg DM, Speights VO. Benign breast disease. Obstet Gynecol Clin North Am. 2008;35:285-300.

Caleffi M, Duarte Filho D, Borghetti K, Graudenz M, Littrup PJ, Freeman-Gibb LA, et al. Cryoablation of benign breast tumors: evolution of technique and technology. Breast. 2004;13(5):397-407.

Kelsey JL, Gammon MD. Epidemiology of breast cancer. Epidemiol Rev. 1990;12(1):228-40.

McDivitt RW, Stevensm JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. Cancer. 1992;69(6):1408-14.

Prajapati SR, Patel KK, Nanavati M. Histopathological Study of Benign Epithelial Lesions of Breast. Inter j scientific research. 2015;7(4):2277-8179.

Dogliotti L, Faggiuolo R, Ferusso A, Orlandi F, Sandrucci S, Tibo A. Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic disease of the breast. Horm Res. 1985;21(3):137-44.

Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-51.

Cheng J, Qiu S, Raju U, Wolman SR, Worsham MJ. Benign breast disease heterogeneity: association with histopathology, age, and ethnicity. Breast Cancer Res Treat. 2008;111(2):289-96.

Courtillot C, Plu-Bureau G, Binart N, Balleyguier C, Sigal-Zafrani B, Goffin V, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005;10(4):325-35.

Shabtai M, Saavedra-Malinger P, Shabtai EL, Rosin D, Kuriansky J, Ravid-Megido M, et al. Fibroadenoma of the breast: analysis of associated pathological entities-a different risk marker in different age groups for concurrent breast cancer. IMAJ-RAMAT GAN-. 2001;3(11):813-7.

Goodwin PJ, Miller A, Del Giudice ME, Singer W, Connelly P, Ritchie JK. Elevated high-density lipoprotein cholesterol and dietary fat intake in women with cyclic mastopathy. Am J Obstetr Gynecol. 1998;179(2):430-7.

Preece PE, Baum M, Mansel RE, Webster DJ, Fortt RW, Gravelle IH, et al. Importance of mastalgia in operable breast cancer. Br Med J (Clin Res Ed). 1982;284(6325):1299-300.

Smith RL, Pruthi S, Fitzpatrick LA. Evaluation and Management of Breast Pain. Mayo Clin Proc. 2004;79:353-72.

Kataria K, Dhar A, Srivastava A, Kumar S, Goyal A. A systematic review of current understanding and management of mastalgia. Indian J Surgery. 2014;76(3):217-22.

Barros AC, Mottola Jr J, Ruiz CA, Borges MN, Pinotti JA. Reassurance in the treatment of mastalgia. Breast J. 1999;5(3):162-5.

Rosolowich V, Saettler E, Szuck B. Mastalgia. J Obste tGynaecol Can. 2006;28:49-74.

Morrow M. The evaluation of common breast problems. Am Fam Physician. 2000;61:2371-8.

Leung JW, Kornguth PJ, Gotway MB. Utility of targeted sonography in the evaluation of focal breast pain. J Ultrasound Med. 2002;21(5):521-6.

Makker A, Tandon I, Goel MM, Singh M, Singh MM. Effect of ormeloxifene, a selective estrogen receptor modulator, on biomarkers of endometrial receptivity and pinopode development and its relation to fertility and infertility in Indian subjects. Fertil Steril. 2009;91(6):2298-307.

Goyal A, Mansel RE. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005;11(1):41-7.

Srivastava A, Mansel RE, Arvind N, Prasad K, Dhar A, Chabra A. Evidence-based management of Mastalgia: a meta-analysis of randomised trials. Breast. 2007;16(5):503-12.

Dhar A, Srivastava A. Role of centchroman in regression of mastalgia and fibroadenoma. World J Surg. 2007;31:1178-84.

Bagale P, Dravid NV, Bagale S, Ahire N. Clinicopathological study of benign breast diseases. Int J Health Sci Res.2013;3(2):47-54.

Kulkarni S, Vora IM, Ghorpade KG, Shrivastava S. Histopathological spectrum of breast lesions with reference to uncommon cases. Obste Gynecol India. 2009;59(5):444-52.

Malik M, Salahuddin O, Azhar M, Dilawar O, Irshad H, Sadia SA. Breast diseases; spectrum in Wah cantt; POF hospital experience. Professional Med J. 2010;17(3):366-72.

Pudale S, Tonape SD. A histopathological study of non-malignant breast lesions. Inter J Res Med Sci. 2015;3(10):2672.

Kumar AD, Jayashankar E, Shailaja P, Ramamurti T. Expression of Estrogen, Progesterone and HER2/ neu Receptors in Breast Carcinoma- Study in a Tertiary Care Hospital. J Evolut Med Dent Sci. 2015;4(58):10170-7.

Rasheed A, Sharma S, Mohsin-ul-Rasool, Bashir S, Hafiz A, BashirSch N. A Three Year Study of Breast Lesions in Women aged 15-70 years in a Tertiary Care Hospital. J App Med Sci. 2014;2(1):166-8.

Sarma U, Deka R, Deuri S. ER & PR Status of Breast Cancer – A Single Center Study From Guwahati, North East India. Ind J App Res. 2015;5(7):283-4.

Sangma MBM, Panda K, Dasiah S. A Clinico-Pathological Study on Benign Breast Diseases. J Clin Diagn Res. 2013;7(3):503-6.

Amr SS, Abdul Rahman, M Sadi, FazalIlahi, SS Sheikh. The Spectrum of Breast Diseases in Saudi Arab Females: A 26 yr Pathological Survey at Dhahran Health Center. Ann Saudi Med. 1995;15(2):125-32.

Li P, Xiao-Yin T, Cui D, Chi JC, Wang Z. Evaluation of the safety and efficacy of percutaneous radiofrequency ablation for treating multiple breast fibroadenoma. J Cancer Res Ther. 2016;12:138-42.

Godwins E, David D, Akeem J. Histopathologic analysis of benign breast diseases in Makurdi, North Central Nigeria. Inter J Med Med Sci. 2011;3(5):125-8.

Shashikala V, Sonia RP, Victor AJ. Clinicopathological study of benign breast diseases. Int J Biomed Adv Res. 2016;7(9):424-7.

Sagar R, Gaddikeri P, Ramakrishna MK. Analytical study of pattern and presentation of benign breast diseases in patients between age group 15 to 35 years. Int J Biomed Res. 2015;6(6):412-5.

Ramesh K, Bookya K. A study on clinical and pathological correlation of benign breast lesions. Inter Surg J. 2017;4(8):2700-5.

Chalya PL, Manyama M, Rambau PF, Kapesa A, Ngallaba SE, Masalu N, Mabula JB. Clinicopathological pattern of benign breast diseases among female patients at a tertiary health institution in Tanzania. Tanz J Health Res. 2016;18(1).